Dynamics of COVID-19 in Amazonia: A history of government denialism and the risk of a third wave

Ferrante, Lucas; Duczmal, Luiz Henrique; Capanema, Eduardo; Steinmetz, Wilhelm Alexander Cardoso; Almeida, Alexandre Celestino Leite; Leão, Jeremias; Vassão, Ruth Camargo; Fearnside, Philip M.; Tupinambás, Unaí

doi:10.1016/j.pmedr.2022.101752

Cited by 13 publications

(20 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies have shown that they are effective against the disease among the elderly, which could explain the decrease in hospitalizations in this age group during the initial months of 2021, internationally and in Brazil [13][14][15] . Although vaccination has been shown to be effective, the use of nonpharmacological measures such as the use of masks is still necessary at this time, due to a further increase in cases 16,17 . Among the limitations of this study is the fact that it was carried out in a single department with high complexity, which makes it difficult to extrapolate its results for the entire population.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Hospitalizations for COVID-19 in a tertiary hospital in Brazil: a parallel with vaccination

Salomão

Machado

Fernandes

et al. 2022

Rev. Inst. Med. trop. S. Paulo

View full text Add to dashboard Cite

This study aimed to evaluate the COVID-19 hospitalizations in a tertiary hospital by age group and month, considering the introduction and the advance of the vaccination against the disease. The laboratory-confirmed COVID-19-associated hospitalizations among people aged 20 years or older, that occurred between March 2020 and June 2021, were distributed by month of symptom onset and age group. The proportion of hospitalizations by age group was calculated for the year 2021. The proportions were compared using the chi-square test for trends. The marks of vaccination advances among different age groups were taken from the official website LocalizaSUS. In 2020, hospitalizations among people aged 60-80 years old were the most frequent (39.1%). From January-June 2021, when the vaccination commenced, while hospitalizations of patients aged 20 to < 40 and 40 to 60 years old showed an increasing trend, the older age groups and those with vaccination recommendations (from 60 to < 80 and from 80 or over) showed a downward trend. As of June 2021, with widespread vaccination, a drop in hospitalizations was observed in > 60 years old. At 20 to <40 and 40 to < 60, an increase in hospitalizations was observed. It demonstrates the important role of vaccination in combating the COVID-19 pandemic.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Hospitalizations for COVID-19 in a tertiary hospital in Brazil: a parallel with vaccination

Salomão

Machado

Fernandes

et al. 2022

Rev. Inst. Med. trop. S. Paulo

View full text Add to dashboard Cite

show abstract

“…Moreover, global researchers continue to leave no stone unturned to find specific therapies for the management of COVID-19 patients [1,2]. However, some countries have been hit by the second and third waves immediately after easing the lockdown or spatial distancing restrictions [3]. On the other hand, the emergence of novel variants of SARS-CoV-2 has contributed substantially to the rampant increase in cases [4].…”

Section: Introductionmentioning

confidence: 99%

Surveillance of Post-Vaccination Side Effects of COVID-19 Vaccines among Saudi Population: A Real-World Estimation of Safety Profile

Alzarea

Khan²,

Alatawi³

et al. 2022

Vaccines

View full text Add to dashboard Cite

Vaccines are considered to be the most beneficial means for combating the COVID-19 pandemic. Although vaccines against SARS-CoV-2 have demonstrated excellent safety profiles in clinical trials, real-world surveillance of post-vaccination side effects is an impetus. The study investigates the short-term side effects following the administration of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines in Saudi Arabia. A cross-sectional quantitative study was conducted among the general population with age ≥ 18 years, from five regions (Central, Northern, Eastern, Southern, and Western Regions) of Saudi Arabia for a period of 6 months (July to December 2021). A self-administered study instrument was used to record the side effects among the COVID-19 vaccine recipients. Of the total 398 participants (males: 59%), 56.3% received Pfizer and 43.7% were vaccinated with AstraZeneca. Only 22.6% of respondents received the second dose of the COVID-19 vaccines. The most commonly reported side effects were pain at the injection site (85.2%), fatigue (61.8%), bone or joint pain (54.0%), and fever (42.5%). The average side effects score was 3.4 ± 2.2. Females, young people, and Oxford-AstraZeneca recipients had a higher proportion of side effects. The Oxford-AstraZeneca vaccine recipients complained more about fever (p < 0.001), bone and joint pain (p < 0.001), fatigue (p < 0.001), loss of appetite (p = 0.001), headache (p = 0.008), and drowsiness (p = 0.003). The Pfizer-BioNTech vaccinees had more pain and swelling at the injection site (p = 0.001), and sexual disturbance (p = 0.019). The study participants also reported some rare symptoms (<10%) including heaviness, sleep disturbance, fainting, blurred vision, palpitations, osteomalacia, and inability to concentrate. This study revealed that both Pfizer-BioNTech and Oxford-AstraZeneca administration was associated with mild to moderate, transient, short-lived side effects. These symptoms corroborate the results of phase 3 clinical trials of these vaccines. The results could be used to inform people about the likelihood of side effects based on their demographics and the type of vaccine administered. The study reported some rare symptoms that require further validation through more pharmacovigilance or qualitative studies.

show abstract

“…4 Dentre os estados brasileiros, durante a pandemia da COVID-19, o Amazonas foi considerado um local-chave para o estudo e compreensão de diversos cenários com estrapolação dos resultados em nível mundial, em decorrência do comportamento local dos casos de infecção pelo Sars-CoV-2, o que tornou o estado uma das principais fontes de informações. 5 E frente à enorme quantidade de informações geradas, as ferramentas de Data Science surgem como "um conjunto de princípios fundamentais que apoiam e orientam a extração baseada em princípios de informações e conhecimento dos dados", favorecendo desta forma a obtenção de informações precisas para tomadas de decisões a partir do processamento (mineração) de grandes volumes de dados. 6 Desta forma, foi proposta a presente pesquisa que teve por objetivo utilizar ferramentas de Data Science para analisar se o acometimento por COVID-19 no Amazonas aumentava o risco de ocorrência de óbitos em pacientes que desenvolveram SRAG e concomitantemente apresentavam alguma comorbidade associada.…”

Section: Introductionunclassified

Influência das comorbidades para a ocorrência de óbitos por COVID-19 em 2020: razão de chances no estado do Amazonas

Rosa¹,

Filho²,

Linhares³

2022

hu rev

View full text Add to dashboard Cite

Introdução: O vírus Sars-CoV-2 da família dos coronavírus foi descoberto em dezembro de 2019 na República Popular da China, na cidade de Wuhan, foco inicial da pandemia da doença do coronavírus 2019 (COVID-19). Essa doença ocasionou diversos óbitos mundialmente e a presença de comorbidades foi associada com o aumento dessas ocorrências. Objetivo: Utilizar ferramentas de Data Science para analisar se o acometimento por COVID-19 no Amazonas aumentava o risco de ocorrência de óbitos em pacientes que desenvolveram síndrome respiratória aguda grave (SRAG) e concomitantemente apresentavam alguma comorbidade associada. Material e Métodos: Estudo observacional retrospectivo do tipo caso-controle pareado a partir de dados de SRAG disponíveis no OpenDataSUS, pelo Ministério da Saúde, utilizando linguagem de programação Python e a biblioteca Pandas. Resultados: Constatou-se 17.924 casos de COVID-19 em 2020 no Amazonas, desses 5.882 pacientes vieram a óbito. Dentre os casos de óbitos decorrente de COVID-19, verificou-se que 68,74% apresentavam alguma comorbidade associada. Ao comparar os grupos de acordo com a exposição e a ocorrência de desfecho, verificou-se que a exposição à COVID-19 em pacientes com comorbidades associadas aumentou o risco para ocorrência de óbitos, exceto quando presente síndrome de Down. A comorbidade mais prevalente entre os casos de COVID-19 foi a doença cardiovascular crônica (47,84%) e a mais letal foi a doença renal crônica (62,23%). Conclusão: Este estudo demonstrou que o acometimento por COVID-19 aumentou a chance de ocorrência de óbitos em indivíduos com comorbidades que desenvolveram SRAG em 2020 no Amazonas, além de explicitar o impacto negativo dos acometimentos cardiovasculares sobre a progressão da COVID-19.

show abstract

Dynamics of COVID-19 in Amazonia: A history of government denialism and the risk of a third wave

Cited by 13 publications

References 35 publications

Hospitalizations for COVID-19 in a tertiary hospital in Brazil: a parallel with vaccination

Hospitalizations for COVID-19 in a tertiary hospital in Brazil: a parallel with vaccination

Surveillance of Post-Vaccination Side Effects of COVID-19 Vaccines among Saudi Population: A Real-World Estimation of Safety Profile

Influência das comorbidades para a ocorrência de óbitos por COVID-19 em 2020: razão de chances no estado do Amazonas

Contact Info

Product

Resources

About